The U.S. Department of Health and Human Services (HHS) is moving to expand access to six unapproved peptides, raising concerns about patient safety, FDA oversight, and the lack of clinical evidence supporting their use. The new policy allows certain licensed pharmacies to compound these substances under specific conditions, despite ongoing questions about their safety and effectiveness.

On October 28, the U.S. Department of Health and Human Services (HHS), led by Secretary Robert F. Kennedy Jr., issued an interim enforcement policy outlining circumstances in which licensed pharmacies and physicians may compound certain peptide substances without facing federal enforcement action.

The policy covers six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. These substances have gained attention in online wellness communities, where they are promoted for potential benefits involving muscle recovery, inflammation, sleep, cognitive function and metabolic health.

However, none of the six peptides has received FDA approval for these uses, and their safety and effectiveness have not been established through the agency’s standard drug review process.

Peptides are short chains of amino acids that perform important biological functions. Some peptide-based medicines, including insulin and certain medications used to treat diabetes and obesity, have received FDA approval after clinical testing. The six substances covered by the new policy are different because sufficient clinical evidence supporting their safety and effectiveness remains unavailable.

Under the HHS policy, qualifying compounders must meet several conditions, including obtaining ingredients from appropriately registered manufacturers, verifying product identity and purity, using patient-specific prescriptions, and reporting serious adverse events and product-quality problems.

HHS argues that providing access through licensed healthcare professionals and pharmacies could reduce reliance on unregulated online sellers offering substances of uncertain quality.

In its policy, HHS described the approach as providing patients with a “more controlled alternative” while federal regulators continue evaluating the substances.

The decision follows a July 2026 meeting in which an FDA advisory committee recommended allowing the six peptides to be considered for pharmacy compounding. However, according to Associated Press reporting, FDA scientific staff had opposed relaxing restrictions because of insufficient evidence supporting the substances’ safety and effectiveness.

The FDA has previously identified potential risks associated with certain compounded peptides, including unexpected immune responses, impurities and limited human safety data. These concerns are especially important for injectable products, where contamination or inaccurate dosing can create additional health risks.

Dr. Peter Lurie, a former FDA official who now leads the Center for Science in the Public Interest, also expressed concern to the Associated Press that patients could move away from established treatments toward products without adequate supporting evidence.

What the Policy Means for Patient Safety and Health Access

The federal action creates a distinction that patients and healthcare providers must understand: allowing certain compounded products under an enforcement-discretion policy is not the same as confirming that those products are safe, effective or FDA-approved.

Compounded medications can play an important role in healthcare, particularly when an approved medication cannot meet an individual patient’s specific medical needs. However, unlike FDA-approved medicines, compounded drugs are not reviewed by the FDA for safety, effectiveness or quality before they are marketed.

The new policy attempts to address some of those concerns through manufacturing, testing and reporting requirements. Still, safeguards governing how a product is prepared cannot replace clinical studies determining whether a substance actually benefits patients or what its long-term risks may be.

For patients managing chronic conditions, persistent pain or other health concerns, products promoted as innovative solutions can be appealing, particularly when existing treatments have not delivered the desired results. But patients need clear, reliable information about the difference between promising preliminary research, marketing claims and treatments supported by rigorous clinical evidence.

Questions about access also extend beyond product availability. Patients should have access to qualified healthcare professionals who can explain the available evidence, discuss possible adverse effects and identify established treatment options. That includes people who already encounter barriers to affordable, continuous and culturally responsive healthcare.

Anyone considering a compounded peptide should discuss the available evidence with a licensed healthcare professional, confirm that the dispensing pharmacy is appropriately licensed, and understand whether the product has received FDA approval. Patients should also ask how the product’s quality is verified and what steps to take if unexpected symptoms occur.

The HHS policy remains temporary while the federal government develops more permanent rules governing the substances. A notice is scheduled for publication in the Federal Register on October 30, with a two-week public comment period following publication. HHS has also indicated that the policy may be reconsidered if new safety concerns or product-quality problems emerge.

As interest in peptide therapies continues to grow, the central challenge for regulators and healthcare providers will be balancing patient access with scientific evidence and meaningful safety protections. Expanding treatment choices may offer new opportunities, but ensuring that patients understand the benefits, uncertainties and potential harms remains essential to protecting public health.

Also Read: World Stroke Day Highlights Prevention and Brain Health Access